S, Cheepudomwit S, Domrongkitchaiporn S, Unkurapinun N, Pakpeankit vatana V, et al. 2007; Kurella M, Lo JC, Chertow GM. 2005; Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. 2 005)
대사증후군 구성요소는 만성신질환과 관련이 있는 것으로 보이며,
여자의 경우 폐경전과 후는 다른 양상을 보이는 것으로 분석되었다. 대사 증후군 구성요소인 중성지방, 혈압, HDL, 허리둘레, 공복혈당 수치는 관 리가 가능한 인자들로 만성 신질환의 위험이 되는 대사증후군을 예방하고 치료하는데 도움이 될 것으로 보여 진다. 또한 여자의 경우 폐경전과 폐 경후의 차이를 보이므로 폐경후 관리가 중요할 것으로 생각된다.
참고문헌
국민건강보험공단, 2011, 2012.
박혜순, 오상우, 강재헌, 박용우, 최중명, 김용성, 최웅환, 유형준, 김형설, 한국인에 대사증후군의 유병률 및 관련요인 2003.
박혜순, 신호철, 김병성, 이가영, 최환석, 신정아, 일차의료에 내원한 성인 에서 대사증후군의 유병률 및 관련요인에 대한 연구.
대한비만학회, 12 (
2), 2003 108-123.보건복지부, 2012.
유지수, 정정인, 박창기, 강세원, 안정아. 생활습관 요인이 대사증후군 유 병 위험에 미치는 영향. 대한간호학회지. 2009;39(4):596-601.
질병관리본부, 2007, 2014
질병관리본부, 국민건강영양조사 제기 원시자료 이용지침서.
통계청, 2011, 2013
한국보건산업진흥원, 2002.
Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of re
nal manifestation of insulin resistance. Kidney Int 2004;65:386-92.
Agrawal S, Shlipak MG, Kramer H, Jain A, Herrington DM. The assoc iation of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis. CardiolRes Pract.2012;2012:806102.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2 009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclero sis Society; and International Association for the Study of Obesity. Ci rculation 120: 1640–1645.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2 009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclero sis Society; and International Association for the Study of Obesity. Ci rculation 120: 1640–1645.
Alberti KG, Zimmet P, Shaw J: IDF Epidemiology Task Force Consen sus Group.
The metabolic syndrome--a new worldwide definition. Lancet 366:10
Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a re cipe for chronic kidney disease? J Am Soc Nephrol 2004;15:2775-9 1.
Beddhu S，Kimmel PL, Ramkumar N，Cheung AK: Association of met abolic syndrome with inflammation in CKD: results from the Third Na tional Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 46：577-586, 2005.
Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ.
Risk of end-stage renal disease in diabetes mellitus: a prospective c ohort study of men screened for MRFIT. Multiple Risk Factor Interve ntion Trial. JAMA 1997;278:2069-74.
Braun, S., Bitton-Worms, K., & LeRoith, D. (2011). The link betwee n the metabolic syndrome and cancer.
InternationalJournalofBiologicalS ciences,7
(7),1003-1015.Carr MC. The emergence of the metabolic syndrome with menopause.
J Clin Endocrinol Metab 2003; 88: 2404-11
Chang IH, Han JH, Myung SC, et al. Association between metabolic s yndrome and chronic kidney disease in the Korean population. Nephro logy(Carlton).2009;14(3):321–326.
Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and ch
ronic kidney disease in US adults. AnnInternMed.2004;140(3):167–17 4.
Cheng HT, Huang JW,Chiang CK,Yen CJ,Hung KY,Wu KD: Metabolic s yndrome and insulin resistance as risk factors for development of chr onic kidney disease and rapid decline in renal functioninelderly. JClin Endocrino Meta 2012;97:1268-76.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P,Van L ente F, Levey AS.Prevalence of chronic kidney disease in the United States.
JAMA2007;298:2038-47.
Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachuse tts Women's Health Study. Menopause 2000; 7: 96-104.
Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabol ic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Cir culation 2007;116:2119-2126.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
Ervin, R. B.(2009). Prevalence of metabolic syndrome among adults 2
0 years of
age and over, by sex, age, race and ethnicity, and body mass index:
United States, 2003-2006.
NationalHealthStatisticsReports,13,
1-8.Esmailnasab, N., Moradi, G.& Delaveri, A.(2012). Risk factors of non -communicable diseases and metabolic syndrome.
IranianJournalofPubl icHealth.41
(7),
77-85.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, An d Treatment of High Blood Cholesterol In Adults (Adult Treatment P anel III). JAMA 285:2486-2497, 2001.
Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinemia:th e key feature of a cardiovascular and metabolic syndrome. Diabetolosi a 34: 416-422, 1991.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutritio n Examination Survey.
JAMA
.2002;287(3):356–359.Ford.E.S, Giles.W.H, Mokdad.A.H, Increasing prevalence of the metab olic syndrome among U.S. adults, Diabetes, 2004;27(10);2444-2449.
Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycem ic status and development of kidney disease: the Framingham Heart S tudy. Diabetes Care 2005;
28:2436-40.
Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Mora1es PA, Stern MP: Prospective analysis of the insulin-resistance syndrome (syndro me X). Diabetes 41: 715-722, 1992.
Hanley AJ, Karter AJ, Williams K, Festa A, D'Agostino RB Jr, Wagen knecht LE, et al. Prediction of type 2 diabetes mellitus with alternati ve definitions of the metabolic syndrome: the Insulin Resistance Athe rosclerosis Study. Circulation 2005; 112:3713-21.
IDF Press Conference. The IDF consensus worldwide definition of the metabolic
syndrome.
Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, et al. (2009) Pr evalence of chronic kidney disease in the Japanese general population.
Clin Exp Nephrol 13: 621–630.
Ishii S, Tanaka T, Akishita M, Ouchi Y, Tuji T, Iijima K, et al. Meta bolic syndrome, sarcopenia and role of sex and age: cross-sectional analysis of kashiwa cohort study. PLoS One 2014;9:e112718.
Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al.
Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.; 9.
Jing C, Paul M, Lee H, Daniel WJ, Vecihi B, Vivian F, Paul KW, Jian g H. The Metabolic syndrome and Chronic Kidney Disease in U.S. Ad ults. Ann Intern Med 2004;140:167-174.
Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines fo r chronic kidney disease in adults: part I. Definition, disease stages, evaluation, treatment, and risk factors. AmFamPhysician.2004;70(5):8 69-876.
Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines fo r chronic kidney disease in adults: part I. Definition, disease stages, evaluation, treatment, and risk factors. AmFamPhysician.2004;70(5):8 69-876.
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney dise ase in a large managed care organization. ArchInternMed.2004;164(
6):659-663.
Kim MH, Kim MK, Choi BY, Shin YJ. Prevalence of the metabolic sy ndrome and its association with cardiovascular diseases in Korea. J K orean Med Sci 2004; 19:195-201.; 11.
Kinchen K, Sadler J, Fink N, et al: The timing of specialist evaluatio n in chronic kidney disease and mortality. Ann Intern Med 137:479-483, 2002
Kitiyakara C, Yamwong S, Cheepudomwit S, Domrongkitchaiporn S, U nkurapinun N, Pakpeankitvatana V, et al. The metabolic syndrome and chronic kidney disease in a Southeast Asian cohort. Kidney Int 2007;
71:693-700.
Korea Centers for Disease Control and Prevention. 2012. Study on th e Socioeconomic Burden of Chronic Kidney Disease.
Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among non diabetic adults. J Am Soc Nephrol 2005;16:2134-40.
Kurella M，Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 1 6: 2134-2140, 2005.
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tu omilehto J. The metabolic syndrome and total and cardiovascular dise ase mortality in middle-aged men. JAMA 2002:288:2709-2716.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A mor e accurate method to estimate glomerular filtration rate from serum c reatinine: A new prediction equation. Ann Intern Med 130:461-470, 1999 17.
Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtratio n rate with standardized serum creatinine values. ClinChem.2007;53 (4):766-772.
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a positio n statement from Kidney Disease: Improving Global Outcomes (KDIG O). Kidney Int 2005;67:2089-100.
Levey AS, Greene T, Kusek J, Beck G: A simplified equation to predi ct glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:155A, 2000.
Lim S, Park KS, Lee HK, Cho SI. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determin ed by Korean National Health and Nutrition Examination Surveys. Dia betes Care 2005;28:1810-1812.
Lim S, Shin H, Song JH, et al. Increasing prevalence of metabolic sy ndrome in Korea. Diabets Care 2011;34(6):1323-1328.
Locatelli F, Pozzoni P, Vecchio LD, Renal manifestations in the metab olic syndrome. J Am Soc Nephrol. 2006;17:S81-S85.
Mozumdar A, Liguori G. Persistent increase of prevalence of metaboli c syndrome among U.S. adults: NHANES III to NHANES 1999-2006.
Diabetes Care 2011; 34:216–219.
National Kidney Foundation [NKF]. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. AmJKidneyDis.2007;49(Suppl2):S1-S180.
NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical Practice Guideli nes for Chronic Kidney Disease: Evaluation, Classification and Stratific ation. AmJKidneyDis39(Suppl1):S1–S266, 2002
Othman M, Kawar B, El Nahas AM. Influence of obesity on progressi on of non-diabetic chronic kidney disease: a retrospective cohort stu dy.
NephronClinPract
2009;113:c16-c23[PMID:19590231DOI:10.1159/0 00228071].Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE. A central body fat distribution is related to renal function i mpairment, even in lean subjects. Am J Kidney Dis 2003;41:733-41.
Reaven GM. Banting Lecture 1988.Role of insulin resistance in human disease. Diabetes.1988:37(12):1595-1607.
Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and re gression of renal lesions of chronic nephropathies and diabetes. JClinI
Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently h ealthy men. J Am Soc Nephrol 2003;14:2084-91
Snively CS, Gutierrez C. Chronic kidney disease: prevention and treat ment of common complications. AmFamPhysician.2004;70:1921-1928, 1929-1930.
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney functio n— measured and estimated glomerular filtration rate. NEnglJMed.200 6;354(23):2473-2483.
Stevens LA, Levey AS. Current status and future perspectives for C KD testing. AmJKidneyDis2009;53(suppl3):S17–26.
Suh S, Lee MK. Metabolic syndrome and cardiovascular diseases in K orea. J Atheroscler Thromb 2014;21 Suppl 1:S31-S35.
Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan.
KidneyInt
2006;69:369-74.The Korean National Health and Nutrition Examination Survey for 19 98–2007
Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navanee
than SD. Metabolic syndrome and kidney disease: a systematic revie w and meta-analysis. ClinJAmSocNephrol2011;6:2364-2373[PMID:21 852664DOI:10.2215/CJN.02180311.
Thomas GN, Ho S Y ，Janus E D ，Lam K S ，Hedley A J, Lam T H ； Hong Kong Cardiovascular R isk Factor Prevalence Study Steeri ng Committee: The U S National Cholesterol Education Programme A dult Treatment Panel III (NCEP-ATP III) prevalence of the metaboli c syndrome in a Chinese population. Diabetes Res Clin Pract 67: 251 -257, 2005.
United States Renal Data System. 2014 Annual Data Report, Vol. 2, Chapter 10: International Comparisons, ].
Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney dis ease: a position statement from the National Kidney Foundation. AmJ KidneyDis2007;50:169–80.
WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization 31–
33, 1999.
Abstract
component of metabolic syndrome and relation with chronic kidney di sease
-5th KOREA National Health and Nutrition Examination Survey-Soonyoung Lee Graduate School of Public Health Ajou University (Supervised by Professor Ki Hong Chun, M.D., Ph.D)
This study will evaluate the relation of chronic kidney disease with a combination of components of the metabolic syndrome. For thi s study, 5th KOREA National Health and Nutrition Examination Surve y at 2010, 2011, and 2012 were used. In the data subjects are 19,18 5 out of a total of 25,534 people over the age of 20. We compared t he distribution of chronic kidney disease with each combination of me tabolic syndrome in people with the metabolic syndrome components, resulting in observing the relevance of chronic kidney disease.
Among subjects over 20 year old, in case of increased age, m arried, educated, low income, and unemployed subjects, the metabolic syndrome is higher than other subjects. CKD prevalence was 2.7%, a nd chronic kidney disease prevalence in subjects with the metabolic s yndrome was 5.1% of men, 0.5% of women pre menopausal, and 7.
5% of women post menopause. In case of woman, pre and post meno pause has been showed a big difference.
As a result of comparing the relevance of chronic kidney dise
ase with non-metabolic syndrome and combination of the metabolic s yndrome components, combination of metabolic syndrome components was analyzed to be associated with chronic kidney disease.
By logistic regression analysis to determine the relation betwe en the metabolic syndrome components and chronic kidney disease, a high odd ratio with chronic kidney disease was not shown in group w ith metabolic syndrome, but group with metabolic syndrome. In case of woman, pre and post menopause was analyzed to be followed a dif ferent pattern.
Metabolic syndrome is related to renal dysfunction and chronic kidney disease. Metabolic syndrome components, fasting blood glucos e, blood pressure, and HDL cholesterol, are controllable, and this stud y can provide a significant database for the prevention of chronic kid ney disease related to their components.